[1] Gibney GT, Weiner LM, Atkins MB. Predictive biomarkers for checkpoint inhibitor-based immunotherapy [J]. Lancet Oncol, 2016, 17(12): e542-e551. DOI: 10.1016/S1470- 2045(16)30406-5.
[2] Ji HH, Tang XW, Dong Z, et al. Adverse event profiles of anti-CTLA-4 and anti-PD-1 monoclonal antibodies alone or in combination: analysis of spontaneous reports submitted to FAERS [J]. Clin Drug Investig, 2019, 39(3):319-330. DOI: 10.1007/s40261-018-0735-0.
[3] Chang LS, Barroso-Sousa R, Tolaney SM, et al. Endocrine toxicity of cancer immunotherapy targeting immune checkpoints [J]. Endocr Rev, 2019, 40(1): 17-65. DOI:10.1210/er.2018-00006
[4] Friedman CF, Proverbs-Singh TA, Postow MA. Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review [J]. JAMA Oncol, 2016, 2(10): 1346-1353. DOI: 10.1001/jamaoncol.2016.1051.
[5] Barroso-Sousa R, Barry WT, Garrido-Castro AC, et al. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis [J]. JAMA Oncol, 2018, 4(2): 173-182. DOI: 10.1001/jamaoncol.2017.3064.
[6] Zhou Y, Xia R, Xiao H, et al. Thyroid function abnormality induced by PD-1 inhibitors have a positive impact on survival in patients with non-small cell lung cancer [J]. Int Immunopharmacol, 2021, 91: 107296. DOI:10.1016/j.intimp.2020.107296.
[7] Byun DJ, Wolchok JD, Rosenberg LM, et al. Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies [J]. Nat Rev Endocrinol, 2017, 13(4): 195-207. DOI: 10.1038/nrendo.2016.205.
[8] Zhao Z, Wang X, Bao XQ, et al. Autoimmune polyendocrine syndrome induced by immune checkpoint inhibitors: a systematic review [J]. Cancer Immunol Immunother, 2021, 70(6):1527-1540. DOI: 10.1007/s00262-020- 02699-1.
[9] Almutairi AR, McBride A, Slack M, et al. Potential immune-related adverse events associated with monotherapy and combination therapy of ipilimumab, nivolumab, and pembrolizumab for advanced melanoma: a systematic review and meta-analysis [J]. Front Oncol, 2020, 10: 91. DOI: 10.3389/fonc.2020.00091.
[10] de Filette J, Andreescu CE, Cools F, et al. A systematic review and meta-analysis of endocrine-related adverse events associated with immune checkpoint inhibitors [J]. Horm Metab Res, 2019, 51(3): 145-156. DOI:10.1055/a-0843-3366.
[11] 廖佳伟,胡晓庆,杨毅. 乳腺癌根治术患者放化疗前后甲状腺功能变化情况及其临床意义[J]. 昆明医科大学学报,2022,43(2):72-77. DOI:10.12259/j.issn.2095-610X.S20220229.
[12] 李新. 鼻咽癌调强放疗后甲状腺功能减退研究[D].乌鲁木齐:新疆医科大学,2021. DOI:10.27433/d.cnki.gxyku.2021. 000257.
|
